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A BS TR AC T
BACKGROUND
A window of opportunity has been suggested for reducing the risk of celiac disease 
by introducing gluten to infants at 4 to 6 months of age.
METHODS
We performed a multicenter, randomized, double-blind, placebo-controlled dietary-
intervention study involving 944 children who were positive for HLA-DQ2 or HLA-
DQ8 and had at least one first-degree relative with celiac disease. From 16 to 24 
weeks of age, 475 participants received 100 mg of immunologically active gluten 
daily, and 469 received placebo. Anti–transglutaminase type 2 and antigliadin an-
tibodies were periodically measured. The primary outcome was the frequency of 
biopsy-confirmed celiac disease at 3 years of age.
RESULTS
Celiac disease was confirmed by means of biopsies in 77 children. To avoid under-
estimation of the frequency of celiac disease, 3 additional children who received a 
diagnosis of celiac disease according to the 2012 European Society for Pediatric 
Gastroenterology, Hepatology, and Nutrition diagnostic criteria (without having 
undergone biopsies) were included in the analyses (80 children; median age, 2.8 years; 
59% were girls). The cumulative incidence of celiac disease among patients 3 years 
of age was 5.2% (95% confidence interval [CI], 3.6 to 6.8), with similar rates in the 
gluten group and the placebo group (5.9% [95% CI, 3.7 to 8.1] and 4.5% [95% CI, 
2.5 to 6.5], respectively; hazard ratio in the gluten group, 1.23; 95% CI, 0.79 to 1.91). 
Rates of elevated levels of anti–transglutaminase type 2 and antigliadin antibodies 
were also similar in the two study groups (7.0% [95% CI, 4.7 to 9.4] in the gluten 
group and 5.7% [95% CI, 3.5 to 7.9] in the placebo group; hazard ratio, 1.14; 95% 
CI, 0.76 to 1.73). Breast-feeding, regardless of whether it was exclusive or whether 
it was ongoing during gluten introduction, did not significantly influence the de-
velopment of celiac disease or the effect of the intervention.
CONCLUSIONS
As compared with placebo, the introduction of small quantities of gluten at 16 to 
24 weeks of age did not reduce the risk of celiac disease by 3 years of age in this 
group of high-risk children. (Funded by the European Commission and others; 
PreventCD Current Controlled Trials number, ISRCTN74582487.)
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Celiac disease, an immune-mediated systemic disorder elicited by gluten in ge-netically susceptible persons, is charac-
terized by anti–transglutaminase type 2 antibod-
ies (TG2A) and enteropathy.1 The prevalence of 
celiac disease is 1 to 3% in the general population 
and approximately 10% among first-degree fam-
ily members of patients with celiac disease.2-10 
Celiac disease is treated with a gluten-free diet. 
More than 95% of patients have the HLA-DQ2 
heterodimer, either in the cis or trans configura-
tion. Most of the remaining patients have the 
HLA-DQ8 heterodimer or half of the HLA-DQ2 
heterodimer (DQB1*02).1,8,11-14 However, more 
than 25% of the general population has these 
haplotypes,8,13 indicating that additional factors 
are involved in disease development.
Celiac disease increases the overall risk of 
death,15 reduces quality of life,16 and has exten-
sive negative economic consequences.17,18 The 
health and quality of life of patients improve 
with a gluten-free diet, but primary prevention 
would be more beneficial.19,20 Results from 
observational studies indicate that the develop-
ment of oral tolerance for gluten is initiated 
early in life and that the mode of introducing 
gluten to infants may influence the risk of ce-
liac disease in predisposed persons.21-25 The 
results of these studies suggest that there is a 
window of opportunity at 4 to 6 months of age, 
when the first exposure to gluten should occur 
in order to decrease the risk of celiac disease.24,25 
The results of studies evaluating breast-feeding 
and the risk of celiac disease are inconclusive, 
since most of these studies were retrospective 
and associated with parental recall bias, and 
none included randomization or specified the 
quantities of gluten consumed.23-27 At present, 
the true influence of early feeding on the de-
velopment of celiac disease remains contro-
versial.
To investigate the possible primary preven-
tion of celiac disease, the European multicenter 
project Prevent Coeliac Disease (PreventCD, 
www.preventcd.com) was initiated.19 It was hy-
pothesized that the frequency of celiac disease 
at 3 years of age could be reduced by exposing 
genetically predisposed infants to small quanti-
ties of gluten at 16 to 24 weeks of age, preferably 
while they were still being breast-fed.
ME THODS
STUDY DESIGN AND PARTICIPANTS
We performed a prospective, randomized, double-
blind, placebo-controlled, dietary-intervention 
study. The first child was included on May 26, 
2007, and the follow-up for this analysis closed 
on September 10, 2013, when the youngest study 
participant turned 3 years of age; the oldest par-
ticipants were up to 6 years of age. Infants 0 to 
3 months of age were recruited consecutively 
through celiac-disease organizations in Croatia, 
Germany, Hungary, Israel, Italy, the Netherlands, 
Poland, and Spain. Infants were required to have 
the HLA-DQ2, HLA-DQ8, or HLA-DQB1*02 het-
erodimer (centrally typed) and to have at least 
one first-degree family member with celiac dis-
ease, as confirmed by means of small-bowel 
biopsies. We excluded premature infants and 
those with trisomy 21 or Turner’s syndrome (see 
the Supplementary Appendix, available with the 
full text of this article at NEJM.org).
INTERVENTION
We randomly assigned participants to receive either 
200 mg of vital wheat gluten mixed with 1.8 g of 
lactose (equivalent to 100 mg of immunologically 
active gluten) or placebo (2 g of lactose), given daily 
for 8 weeks starting at 16 weeks of age (see the 
Supplementary Appendix). Previous assessment of 
the vital wheat gluten by means of enzyme-linked 
immunosorbent assay and Western blot analysis 
had shown the presence of gluten proteins typically 
found in wheat gluten. Randomization, stratified 
according to participating country, was performed 
with the use of variable block sizes ranging from 
4 to 8 and with SPSS software, version 18.0 (SPSS). 
The investigators and the parents of the participants 
were unaware of the intervention assignments.
Adherence to the study assignment was as-
sessed by means of frequent interviews with the 
parents (Table S1 in the Supplementary Appen-
dix). Participants were considered to have ad-
hered to the intervention assignment if at least 
75% of the study material (gluten or placebo) 
was ingested and no additional gluten was con-
sumed. After the intervention, parents were ad-
vised to introduce gluten gradually, using regu-
lar products and standardized recommendations 
(see the Supplementary Appendix).
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OUTCOMES
The primary outcome was the frequency of celiac 
disease at 3 years of age. The diagnosis of celiac 
disease was based on the histologic findings of 
small-bowel biopsies, according to the 1990 
 criteria of the European Society for Pediatric 
Gastroenterology, Hepatology, and Nutrition 
(ESPGHAN).28 Secondary end points were the 
occurrence of symptoms and the immune re-
sponse to gluten as indicated by elevated serum 
antibodies associated with celiac disease (anti-
gliadin antibodies and TG2A) (see the Supple-
mentary Appendix).
FOLLOW-UP AND ASSESSMENT OF CELIAC DISEASE
We periodically monitored health status, anthro-
pometric variables, and feeding habits (i.e., breast-
feeding and formula feeding), and we quantified 
gluten consumption29 using standardized ques-
tionnaires (Table S1 in the Supplementary Ap-
pendix). Measurements of serum antigliadin an-
tibodies and TG2A were performed centrally at 
least seven times during the first 3 years of age 
and then annually thereafter. The parents of chil-
dren with elevated celiac disease–associated anti-
bodies or with symptoms suggesting celiac dis-
ease were offered small-bowel biopsies to confirm 
the diagnosis in their child (see the Supplemen-
tary Appendix). The biopsy specimens were his-
tologically assessed at the study sites and were 
also reviewed by an author who is a pathologist.30 
The age of the patient when the diagnostic biop-
sies were performed was considered to be the age 
at the diagnosis of celiac disease.
STUDY OVERSIGHT
The study was approved by the medical ethics 
committee at each participating center and com-
plied with Good Clinical Practice guidelines (see 
the Supplementary Appendix). The authors vouch 
for the veracity and completeness of the data and 
analyses reported and for the adherence of the 
study to the protocol, available at NEJM.org.
From 2007 to 2011, the study did not have 
commercial support. After 2011, Thermo Fisher 
Scientific performed antibody assessments with-
out charge, and together with Eurospital and 
Fria Bröd, Thermo Fisher Scientific partly fund-
ed the project progress meetings. The funding 
organizations had no role in the conception, de-
sign, or conduct of the study, in the analysis 
or interpretation of the data, or in the writing of 
the manuscript or the decision to submit it for 
publication.
STATISTICAL ANALYSIS
To detect a 50% reduction in the development of 
celiac disease in the gluten group at 3 years of age 
(5%, vs. 10% with placebo) with a two-sided sig-
nificance level of 5% and with 80% power, we 
calculated that 474 children would be required in 
each group.19 All the data were entered into a Web-
based data-management application with the use 
of a central structured-query-language server data-
base (NEN 7510 certified). A statistical analysis 
plan was published online before the randomiza-
tion codes were opened (http://preventcd.com/ 
images/stories/Publications/PreventCD_SAP_1_0 
.pdf) (see the Supplementary Appendix).
For estimating the cumulative incidence of 
celiac disease, Kaplan–Meier curves were calcu-
lated, with time defined as the patient’s age at the 
diagnosis of celiac disease or at the last assess-
ment or withdrawal from the study (when data 
were censored). For comparison, a log-rank test 
(two-sided) was used, stratified according to 
participating country. The hazard ratio for celiac 
disease in the gluten group, as compared with the 
placebo group (with 95% confidence intervals), is 
provided, on the basis of a Cox proportional-
hazards regression analysis. The primary analysis 
was performed according to the intention-to-treat 
principle. Differences in the cumulative incidence 
of celiac disease were assessed according to the 
baseline variables by means of Cox proportional-
hazards regression (multivariate) analysis and 
according to the duration of breast-feeding, daily 
gluten intake, and occurrence of infection by 
means of a landmark analysis (see the Supple-
mentary Appendix). Different intervention effects 
were assessed in subgroups by including an in-
teraction term between intervention and subgroup 
in the Cox proportional-hazards regression anal-
ysis. Analyses were performed with the use of 
SPSS software, version 20.0 (IBM).
R ESULT S
CHARACTERISTICS OF THE PARTICIPANTS
The parents of 1343 children provided written 
informed consent for the study. A total of 963 
children were randomly assigned to receive glu-
ten (483 participants) or placebo (480) (Fig. 1, 
and the Supplementary Appendix). After ran-
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963 Underwent randomization
80 Received diagnosis of celiac disease
1063 Were positive for HLA-DQ2, 
HLA-DQ8, or both
280 Were negative for HLA-DQ2
and HLA-DQ8
483 Were assigned to gluten group
1343 Patients had informed consent
provided by a parent
480 Were assigned to placebo group
8 Were excluded
4 Were negative for 
   HLA-DQ2 and HLA-DQ8
2 Were premature
2 Had no first-degree 
   relative with celiac disease
11 Were excluded
9 Were negative for 
   HLA-DQ2 and HLA-DQ8
1 Was premature
1 Had no first-degree 
   relative with celiac disease
100 Were excluded
72 Had informed consent
 withdrawn
25 Entered pilot study
3 Had technical error
4 Did not have clear
diagnosis
4 Did not have clear
diagnosis
475 Continued in the study 469 Continued in the study
52 Fulfilled the criteria for diagnostic
small-bowel biopsies


















Figure 1. Randomization and Diagnosed Cases of Celiac Disease.
A total of 25 children were included in a pilot study to test the infrastructure of the study and were not included in the primary analysis. 
A total of 19 children underwent randomization in error and were excluded from the study. On the basis of histologic results of small-
bowel biopsies, active celiac disease was ruled out in 17 children, although 3 of the 17 had potential celiac disease. There was no clear 
diagnosis in 8 asymptomatic children whose parents declined small-bowel biopsies on their behalf and who had transient levels of celiac 
disease–associated antibodies. Celiac disease was diagnosed in 3 children according to the 2012 European Society for Pediatric Gastro-
enterology, Hepatology, and Nutrition diagnostic criteria (without having undergone biopsies).1
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domization, the number of children was reduced 
to 944 because 19 children did not fulfill the in-
clusion criteria. A total of 99 children (10.5%) did 
not adhere to the intervention assignment (59 
children in the gluten group and 40 in the pla-
cebo group). A total of 141 children stopped par-
ticipating before 3 years of age (withdrawal rate, 
14.9%; 69 participants in the gluten group and 
72 in the placebo group). A total of 59 children 
withdrew during the first year (6.2%), 49 during 
the second year (5.2%), and 33 during the third 
year (3.5%); the median follow-up was 4 years 
(range, 22 days to 6.3 years). The reasons for 
withdrawal were unknown for 57% of the chil-
dren, were related to practical issues for 39% 
(e.g., blood sampling or travel distance to cen-
ter), and were related to adverse events for 4% 
(see the Supplementary Appendix).
The baseline characteristics of the children 
were similarly distributed between the interven-
tion groups, with the exception of homozygosity 
for HLA-DQ2 (Table 1). Data on breast-feeding 
were available for 943 children: 882 started 
breast-feeding; at 6 months of age, 527 (55.9%) 
were breast-fed, and 265 (28.1%) were breast-fed 
without complementary feeding except for the 
intervention product. Of the 455 mothers with 
celiac disease, 431 were consuming a gluten-free 
diet during pregnancy and lactation. Rotavirus 
vaccination was performed in 211 children 
(22.4%), either before the intervention (176 chil-
dren) or during the intervention (35).
DIAGNOSIS OF CELIAC DISEASE
The numbers of children who met the criteria to 
undergo small-bowel biopsies are shown in Fig-
ure 1. A total of 101 small-bowel biopsies were 
performed in 94 children (Table 2, and the Sup-
plementary Appendix). Celiac disease was con-
firmed by means of biopsies in 77 children. To 
avoid underestimation of the frequency of celiac 
disease, 3 additional children, whose parents de-
clined biopsies on behalf of their children but 
who met the 2012 ESPGHAN diagnostic criteria,1 
were considered to have celiac disease in all analy-
ses (Fig. 1).
The median age of the 80 children at diagno-
sis was 2.8 years (range, 1.1 to 5.6), and all the 
children had an elevated level of TG2A; 59% 
were girls. The most frequent symptoms were 
abdominal distention (in 20 children) and diar-
rhea (in 19). The cumulative incidence of celiac 
disease at 3, 4, and 5 years of age was 5.2% (95% 
confidence interval [CI], 3.6 to 6.8), 8.8% (95% 
CI, 6.6 to 11.0), and 12.1% (95% CI, 9.2 to 15.0), 
respectively (Table S2 and Fig. S1 in the Supple-
mentary Appendix). Celiac disease was signifi-
cantly more frequent in girls; at 3 years of age, 
the cumulative incidence among girls and boys 
was 7.2% and 3.4%, respectively; at 4 years of 
age, 11.8% and 6.1%; and at 5 years of age, 
14.5% and 9.9% (P = 0.04 by the log-rank test, 
P = 0.02 by multivariate analysis) (Table S2 in the 
Supplementary Appendix). The disease devel-
oped significantly more frequently and earlier in 
the group of children who were homozygous for 
HLA-DQ2 (DR3–DQ2/DR3–DQ2 or DR3–DQ2/
DR7–DQ2) than in the other HLA risk groups,4 
with cumulative incidences at 3, 4, and 5 years 
of age of 14.9%, 23.9%, and 26.9%, respectively 
(P<0.001) (Table S2 and Fig. S2 in the Supple-
mentary Appendix).
Breast-feeding did not influence the develop-
ment of celiac disease. The cumulative inci-
dences at 3 years of age among children who 
were not breast-fed, were breast-fed for 3 or fewer 
months, were breast-fed for 4 or 5 months, or 
were breast-fed for 6 or more months were 7.3%, 
4.4%, 8.2%, and 4.4%, respectively (P = 0.28). 
Similar cumulative incidences at 3 years of age 
were observed among children who were never 
exclusively breast-fed or were breast-fed exclu-
sively for 3 months or less, for 4 or 5 months, 
and for 6 months or more (5.0%, 9.1%, 5.3%, 
and 2.7%, respectively; P = 0.45). Country of ori-
gin and the number and type of affected family 
members were also not related to the develop-
ment of disease (Table S2 in the Supplementary 
Appendix), nor were rotavirus vaccination, gas-
trointestinal or respiratory tract infection, and 
mean daily gluten intake (see the Supplementary 
Appendix).
DEVELOPMENT OF CELIAC DISEASE IN RELATION TO 
THE INTERVENTION
The intervention with gluten, as compared with 
placebo, did not have a significant effect on the 
frequency of development of celiac disease, with 
cumulative incidences at 3 years of age of 5.9% 
(95% CI, 3.7 to 8.1) and 4.5% (95% CI, 2.5 to 6.5), 
respectively (P = 0.47 by a stratified log-rank test; 
hazard ratio, 1.23; 95% CI, 0.79 to 1.91) (Fig. 2A). 
The duration of breast-feeding, whether exclusive 
or not, did not significantly influence the effect 
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Age at end of follow-up for this analysis — yr
Mean 4.9 5.0
Range 3.1–6.5 3.1–6.6
Female sex — no. (%) 228 (48.0) 226 (48.2)
Gestational age — wk
Mean 39.1 39.2
Range 34–43 35–42
Birth weight — g
Mean 3316 3346
Range 1730–5000† 2000–4740
Country — no. (%)
Spain 130 (27.4) 119 (25.4)
Italy 70 (14.7) 69 (14.7)
Hungary 70 (14.7) 68 (14.5)
Netherlands 67 (14.1) 66 (14.1)
Germany 55 (11.6) 58 (12.4)
Israel 47 (9.9) 48 (10.2)
Poland 30 (6.3) 34 (7.2)
Croatia 6 (1.3) 7 (1.5)
HLA risk group — no./total no. (%)‡
1 80/462 (17.3) 49/449 (10.9)
2 46/462 (10.0) 42/449 (9.4)
3 199/462 (43.1) 218/449 (48.6)
4 29/462 (6.3) 37/449 (8.2)
5 108/462 (23.4) 103/449 (22.9)
First-degree relatives with celiac disease — no. (%)
No. of relatives
1 431 (90.7) 432 (92.1)
2 42 (8.8) 32 (6.8)
≥3 2 (0.4) 5 (1.1)
Type of relative
Mother only 200 (42.1) 207 (44.1)
1 sibling 183 (38.5) 184 (39.2)
Father only 48 (10.1) 41 (8.7)
Mother and ≥1 sibling 23 (4.8) 23 (4.9)
>1 sibling but neither parent 12 (2.5) 7 (1.5)
Father and ≥1 sibling 9 (1.9) 5 (1.1)
Mother and father 0 2 (0.4)
* The characteristics of the children were similarly distributed between the intervention groups (P<0.05), with the excep-
tion of homozygosity for HLA-DQ2 (P = 0.05).
† Data included a pair of healthy twins.
‡ Data on the HLA risk group were available for 911 of 944 children, with HLA typing performed by means of single- 
nucleotide polymorphisms (SNPs) on the basis of the tag-SNP approach.8 The HLA risk groups were defined as follows: 
group 1 included DR3–DQ2/DR3–DQ2 (DQ2.5/DQ2.5) and DR3–DQ2/DR7–DQ2 (DQ2.5/DQ2.2); group 2 DR7–DQ2/
DR5–DQ7 (DQ2.2/DQ7); group 3 DR3–DQ2/DR5–DQ7 (DQ2.5/DQ7), DR3–DQ2/DR4–DQ8 (DQ2.5/DQ8), and DR3–
DQ2/other (DQ2.5/other); group 4 DR7–DQ2/DR7–DQ2 (DQ2.2/DQ2.2), DR7–DQ2/DR4–DQ8 (DQ2.2/DQ8), and 
DR4–DQ8/DR4–DQ8 (DQ8/DQ8); and group 5 DR7–DQ2/other (DQ2.2/other), DR4–DQ8/DR5–DQ7 (DQ8/DQ7), 
and DR4–DQ8/other (DQ8/other); “other” refers to any HLA-DQ haplotype except DR3–DQ2, DR7–DQ2, DR4–DQ8, 
or DR5–DQ7. For the remaining 33 children, the status with regard to HLA-DQ2 and HLA-DQ8 positivity was deter-
mined by means of the Eu-Gen Risk test (Eurospital), with no information provided regarding the HLA risk group.
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of the intervention on the development of celiac 
disease (P = 0.70 [for exclusive breast-feeding] 
and P = 0.83 [for nonexclusive breast-feeding] for 
interaction; hazard ratios are provided in Table 
S3 in the Supplementary Appendix).
The cumulative incidence of celiac disease 
was significantly higher among girls randomly 
assigned to gluten than among those randomly 
assigned to placebo: at 3 years of age, the inci-
dence was 8.9% in the gluten group versus 5.5% 
in the placebo group (hazard ratio 1.99; 95% CI, 
1.09 to 3.65; P = 0.02) (Fig. 2B). This difference 
was not seen among boys, with frequencies of 
3.2% in the gluten group and 3.6% in the pla-
cebo group (hazard ratio, 0.62; 95% CI, 0.31 to 
Table 2. Distribution of Symptoms and Celiac Disease–Associated Antibodies in 94 Children with Suspected Celiac Disease 

















Symptoms as indication for biopsy (no.) 52 0 2 13 67
Elevated antibody level as indication for biopsy (no.)‡
TG2A 77 5 0 0 82
Antigliadin antibodies 12 0 0 6 18
Marsh classification of findings in small-bowel 
 biopsies (no.)§
0 0 4 0 13 17
1 0 1 0 1 2
2 3¶ 0 2 3 8
3A 18 0 0 0 18
3B 24 0 0 0 24
3C 32 0 0 0 32
4 0 0 0 0 0
* One child with an elevated TGA2 level underwent biopsy three times: the histologic findings were normal the first two 
times but were compatible with celiac disease the last time. Five children underwent small-bowel biopsies twice. The first 
time, all had normal histologic findings; the second time, two children had normal histologic findings (none had potential 
celiac disease), and three received a diagnosis of celiac disease.
† Potential celiac disease was defined as an elevated level of anti–transglutaminase type 2 antibodies (TG2A) and normal 
histologic findings in the small bowel.
‡ An elevated serum level of IgA TG2A was defined as a level of 6 U per milliliter or more (or in the case of IgA deficiency, 
an IgG TG2A level of ≥10 U per milliliter). An elevated antigliadin antibody level was defined as a level of more than  
50 U per milliliter (or in the case of IgA deficiency, an IgG TG2A level of ≥17 U per milliliter) on three occasions during 
a 3-month period or a level of more than 17 U per milliliter that was clearly increasing in two tests performed during a 
3-month period.
§ Findings on small-bowel biopsies were assessed according to the Marsh classification,30 on a scale of 0 to 4, with 
classes 0 and 1 being not characteristic of celiac disease, class 2 being compatible with celiac disease only with a con-
comitant elevated TG2A level, classes 3A to 3C being characteristic of celiac disease (with higher letter grades indicat-
ing more villous atrophy), and class 4 being characteristic of refractory celiac disease.
¶ Three children had a concomitant elevated TG2A level, as compared with the other five children with a Marsh classifi-
cation of 2.1
Figure 2 (facing page). Cumulative Incidence of Celiac 
Disease.
A total of 75 of 80 children received a diagnosis of celiac 
disease before 5 years of age. The cumulative incidence 
of celiac disease in the gluten group versus the placebo 
group at 3, 4, and 5 years of age was as follows: 5.9% 
versus 4.5%, 10.3% versus 7.3%, and 13.5% versus 10.6%, 
respectively (Panel A). The cumulative incidence among 
454 girls in the gluten group and the placebo group was 
as follows: 8.9% versus 5.5%, 15.1% versus 8.5%, and 
21.0% versus 8.5%, respectively (Panel B). The cumu-
lative incidence among 490 boys was as follows: 3.2% 
versus 3.6%, 5.9% versus 3.6%, and 7.0% versus 13.4%, 
respectively (Panel C). The data in Panels B and C show 
a significant interaction between sex and intervention 
(P = 0.01). The insets show the same data on an expand-
ed y axis.
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1.24; P = 0.17; P = 0.01 for interaction of sex and 
intervention) (Fig. 2C). No factors other than sex 
were found to significantly influence the effect 
of the intervention on the development of celiac 
disease (Fig. 3, and Table S3 in the Supplemen-
tary Appendix).
The results of the primary per-protocol analy-
sis were similar to those of the intention-to-treat 
analysis (see the Supplementary Appendix). The 
cumulative incidence of celiac disease seroposi-
tivity (positive TG2A, positive antigliadin anti-
bodies, or both on two occasions during a 
3-month period) did not differ significantly be-
tween the gluten group and the placebo group 
(7.0% [95% CI, 4.7 to 9.4] and 5.7% [95% CI, 3.5 
to 7.9], respectively; hazard ratio, 1.14 [95% CI, 
0.76 to 1.73]; P = 0.53) (Table 3, and Fig. S3 in the 
Supplementary Appendix). Although elevated 
levels of TG2A were not found in any of the 
participants at 6 months of age, transient anti-
gliadin antibody levels of more than 17 U per 
milliliter were observed in 59 children in the 
gluten group and 2 in the placebo group. This 
elevation was not predictive of celiac disease, 
which developed in only 8 of these children, all 
in the gluten group.
DISCUSSION
Our results indicate that the early introduction 
(at 16 weeks of age) of small quantities of gluten 
did not reduce the risk of celiac disease at 3 years 
of age in genetically predisposed children from 
high-risk families; therefore, our results do not 
support the protective effect that we had hypoth-
esized. In addition, we found that breast-feeding, 
whether exclusive or not, did not have a signifi-
cant effect on the frequency of celiac disease 
among these children. In prespecified secondary 
analyses, we observed an association between the 
early gluten intervention and celiac disease in girls 
but not in boys. We did not find significant ef-
fects in the other subgroups examined, and the 
significant finding in girls may be due to chance 
or to the larger number of girls with HLA-DQ2 
homozygosity who were randomly assigned to 
gluten rather than to placebo (Table S4 in the 
Supplementary Appendix). Owing to the small 
number of children in the different HLA risk 
groups stratified according to sex, we cannot re-
solve this issue.
The higher frequency of celiac disease among 
girls than among boys after early exposure to 
gluten may be related to the well-known in-
creased risk of celiac disease among women,13,31 
but it appears too early in life to be related to the 
protective effect of androgens for autoimmuni-
ty.32 The gut microbiota may also play a role in 
this sexual dimorphism, as was shown recently 
for type 1 diabetes in rodents, in which hor-
mones and microbes together trigger protective 
pathways.32,33 Our results also show prospec-
tively the effect of HLA-DQ2 homozygosity on 
the risk of celiac disease in early childhood.
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0.1
Figure 3. Effect of Intervention Assignment at 16 to 24 Weeks of Age on the 
Development of Celiac Disease in 944 Children from High-Risk Families.
Female sex was the only factor to significantly favor placebo (P = 0.02). The 
HLA risk groups were defined as follows: group 1 included DR3–DQ2/
DR3–DQ2 (DQ2.5/DQ2.5) and DR3–DQ2/DR7–DQ2 (DQ2.5/DQ2.2); 
group 2 DR7–DQ2/DR5–DQ7 (DQ2.2/DQ7); group 3 DR3–DQ2/DR5–DQ7 
(DQ2.5/DQ7), DR3–DQ2/DR4-DQ8 (DQ2.5/DQ8), and DR3–DQ2/other 
(DQ2.5/other); group 4 DR7–DQ2/DR7–DQ2 (DQ2.2/DQ2.2), DR7–DQ2/
DR4–DQ8 (DQ2.2/DQ8), and DR4–DQ8/DR4–DQ8 (DQ8/DQ8); and 
group 5 DR7–DQ2/other (DQ2.2/other), DR4–DQ8/DR5-DQ7 (DQ8/DQ7), 
and DR4–DQ8/other (DQ8/other); “other” refers to any HLA-DQ haplo-
type except DR3–DQ2, DR7–DQ2, DR4–DQ8, or DR5–DQ7. No statistics 
were computed for children from Poland (64 children) and Croatia (13), or 
for children with three or more first-degree relatives with celiac disease (7) 
because of the low number of children with celiac disease in these groups. 
The black boxes represent the hazard ratio with 95% confidence intervals 
(horizontal lines); the size of each box is proportional to the size of the 
corresponding subgroup. The overall estimate is represented by the solid 
vertical line; a dashed vertical line representing no effect is also shown.
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the early development of celiac disease and the 
presence of the disease in one or both parents, 
but this finding should be interpreted with cau-
tion, given the small number of fathers with celiac 
disease in our cohort (105 of 944 fathers). Possi-
ble explanations for the small number of affected 
fathers are the tendency for mothers to be more 
involved in research projects34 and the higher 
frequency of celiac disease among women.13
Contrary to previous reports,35,36 our data 
show that determining the TG2A level, but not 
the level of antigliadin antibodies, is useful in 
the assessment of the presence of celiac disease 
in very young children. In fact, we found that 
symptoms were not prognostic for celiac disease 
(Table 2), indicating that the early determination 
of the TG2A level in genetically predisposed 
children may offer an opportunity for early diag-
nosis.37
The strength of our study lies in its design as 
a randomized, double-blind, placebo-controlled 
trial evaluating a food intervention in a high-risk 
birth cohort, with comprehensive follow-up. The 
cases of celiac disease were assessed in an iden-
tical way, minimizing the risk of bias. Nonethe-
less, our study has some limitations. It may be 
argued that we introduced gluten in a rather 
artificial way, since 100 mg is approximately 2% 
of the amount normally introduced at wean-
ing.29 Nevertheless, this quantity has been 
shown previously to cause histologic damage in 
the intestines of patients with celiac disease.38 
After our gluten intervention, levels of antiglia-
din antibodies were transiently elevated in 59 
children at 6 months of age, showing that 100 
mg of gluten can indeed be immunogenic. Our 
power calculation was based on the assumption 
of a cumulative incidence of celiac disease of 
10% by 3 years of age. We found that the actual 
mean frequency at this age was half the as-
sumed frequency and that it strongly depended 
on sex and HLA haplotype. The confidence in-
tervals for the hazard ratio for the effect of the 
intervention on celiac disease ranged from 0.79 
to 1.91, indicating that we were not able to rule 
out a protective effect smaller than 21% or a 
harmful effect as large as 91%.
Our findings contrast with those from obser-
Table 3. Antibody Elevations and Diagnosis of Celiac Disease According to Intervention Assignment.*








Elevated antibody level at 6 mo of age
Antigliadin 12.4 0.4 <0.001
TG2A 0.0 0.0 NA
Elevated level of TG2A or antigliadin antibody 0.53 1.14 (0.76–1.73)
At 1 yr of age 0.9 0.0
At 2 yr of age 3.2 2.1
At 3 yr of age 7.0 5.7
At 4 yr of age 11.5 9.5
At 5 yr of age 14.0 12.1
Celiac disease 0.47 1.23 (0.79–1.91)
At 1 yr of age 0.0 0.0
At 2 yr of age 2.6 1.9
At 3 yr of age 5.9 4.5
At 4 yr of age 10.3 7.3
At 5 yr of age 13.5 10.6
* NA denotes not applicable.
† The P value for the elevated antibody level at 6 months of age was calculated by means of Fisher’s exact test, and the 
other P values were calculated by means of the log-rank test.
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vational studies suggesting that the introduction 
of gluten between the ages of 4 months and 
6 months represents a window of opportunity 
for preventing celiac disease.23,24 Much of the 
information on infant feeding and the risk of 
celiac disease has been obtained from studies of 
the Swedish celiac disease epidemic, which start-
ed in the mid-1980s21 and was related to the 
introduction of an increased amount of gluten 
after the age of 6 months, when breast-feeding 
became less common.9,22,23,39 However, data re-
garding the timing of gluten introduction in rela-
tion to breast-feeding, as well as the amount of 
gluten, were obtained retrospectively. Our re-
sults also contrast with recent findings in a pro-
spective cohort of young children from the gen-
eral population in Norway.25 However, that study 
investigated only clinically diagnosed celiac dis-
ease, with probable underreporting of celiac 
disease, since most cases are not clinically recog-
nized. Whereas the observations in the Swedish 
and Norwegian cohorts are based on the general 
population from single countries, our results are 
derived from a study population comprising chil-
dren from high-risk families in seven European 
countries and Israel. Observational studies involv-
ing children with an increased risk of type 1 dia-
betes (positive for HLA-DQ2 or HLA-DQ8) have 
had controversial results. Although the results of 
a study conducted in the United States support 
the early introduction of gluten at 4 to 6 months 
of age,24 the age at gluten introduction did not 
influence the risk of celiac disease autoimmu-
nity in a prospective German birth cohort.40
In conclusion, this randomized trial did not 
show the hypothesized benefit of early exposure 
to small quantities of gluten with regard to re-
ducing the incidence of celiac disease among 
children from high-risk families. In addition, we 
did not observe a reduced risk of celiac disease 
associated with the maintenance of breast-feed-
ing at the time of gluten introduction. The pres-
ent European guidelines recommend the intro-
duction of small amounts of gluten gradually 
while the child is breast-fed and the avoidance of 
both the early (<4 months) or late (>7 months) 
introduction of gluten.41 Our results do not pro-
vide evidence to support these guidelines or any 
specific feeding recommendation with respect 
to the timing of gluten introduction for infants 
at risk for celiac disease.
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